Literature DB >> 27656463

The rs2070895 (-250G/A) Single Nucleotide Polymorphism in Hepatic Lipase (HL) Gene and the Risk of Coronary Artery Disease in North Indian Population: A Case-Control Study.

Pratima Verma1, Dileep Kumar Verma2, Rishi Sethi3, Shraddha Singh4, Akhilesh Krishna5.   

Abstract

INTRODUCTION: Several Single Nucleotide Polymorphisms (SNPs) in lipid transport genes have been shown to be associated with Coronary Artery Disease (CAD). The Hepatic Lipase (HL)glycoprotein is a key component that catalyzes the hydrolysis of triglycerides and phospholipids in all major classes of lipoproteins. AIM: We studied whether the HL gene-250G/A polymorphism affect blood lipid level and the CAD in a North Indian population.
MATERIALS AND METHODS: A total number of 477 subjects were enrolled in the study after approval of the Institutional Ethics Committee. Out of 477 subjects, 233 were with coronary artery disease as study group and 244 subjects without coronary artery disease as control group. All subjects recruited with matched ethnicity in age group of 40-70 years. Blood samples were collected in EDTA vials and genomic DNA was extracted from blood using the phenol-chloroform method. Lipid profile was estimated by using a commercially available kit. Polymorphisms in the HL (-250 G/A) gene were analysed by using restriction fragment length polymorphism-polymerase chain reaction (PCR-RFLP) method. The effect of this polymorphism on plasma lipids, lipoproteins and coronary artery disease was determined.
RESULTS: In Human Hepatic Lipase (LIPC)-250G/A genotype, the frequencies of GG, GA and AA genotype in CAD group was 80.69%, 15.45% and 3.86%, respectively; in the control group, the corresponding frequencies were 90.16%, 9.02% and 0.82%, respectively. A significant difference was found in the genotype (LIPC-250G/A) distribution between the two groups. Further logistic regression analysis indicated that the GA and AA genotypes in SNP-250G/A were significantly associated with CAD in all genetic models (In codominant model- GA vs. GG, OR=1.91, 95% CI=1. 09-3.37, p=0. 03 and AA vs. GG, OR= 5.26, 95% CI= 1.10-24.60, p=0.04; in dominant model- GA+AA vs. GG, OR=2.19, p=0.004 and in recessive model- AA vs. GG+GA, OR=5.26, p=0.04 whereas, A allele at nucleotide -250G/A in the LIPC gene had an association with increased risk of CAD (OR=2.33, p=<0.008).
CONCLUSION: Our findings indicated that the higher frequency of a dominant model (GA+AA) as well as mutant allele A of LIPC-250 G/A polymorphism is significantly associated with risk of CAD and the lipid profile can be used as a predictor of CAD.

Entities:  

Keywords:  HDL-C; HL activity; LIPC gene; Low density lipoprotein; Polymorphisms

Year:  2016        PMID: 27656463      PMCID: PMC5028592          DOI: 10.7860/JCDR/2016/20496.8378

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  65 in total

Review 1.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

2.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

Review 3.  Recent trends in coronary heart disease epidemiology in India.

Authors:  Rajeev Gupta
Journal:  Indian Heart J       Date:  2008 Mar-Apr

4.  Clustering of cardiovascular risk factors in urban Asian Indians.

Authors:  A Ramachandran; C Snehalatha; E Latha; K Satyavani; V Vijay
Journal:  Diabetes Care       Date:  1998-06       Impact factor: 19.112

5.  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study.

Authors:  G S Berenson; S R Srinivasan; W Bao; W P Newman; R E Tracy; W A Wattigney
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

6.  Fat intake influences the effect of the hepatic lipase C-514T polymorphism on HDL-cholesterol levels in children.

Authors:  Pía Riestra; Laura López-Simón; Henar Ortega; Lydia Gorgojo; José M Martin-Moreno; Stefanie Schoppen; Manuel de Oya; Carmen Garcés
Journal:  Exp Biol Med (Maywood)       Date:  2009-05-08

7.  Association between -250G/A polymorphism of the hepatic lipase gene promoter and coronary artery disease and HDL-C levels in a Southern Brazilian population.

Authors:  F M de Andrade; F R Silveira; M Arsand; A L S Antunes; M R Torres; A J Zago; S M Callegari-Jaques; M H Hutz
Journal:  Clin Genet       Date:  2004-05       Impact factor: 4.438

Review 8.  Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet.

Authors:  Samir S Deeb; Alberto Zambon; Molly C Carr; Amir F Ayyobi; John D Brunzell
Journal:  J Lipid Res       Date:  2003-03-16       Impact factor: 5.922

Review 9.  How to calculate sample size for different study designs in medical research?

Authors:  Jaykaran Charan; Tamoghna Biswas
Journal:  Indian J Psychol Med       Date:  2013-04

10.  The -514C/T Polymorphism of Hepatic Lipase Gene among Iranian Patients with Coronary Heart Disease.

Authors:  K Ghatreh Samani; M Noori; M Rohbani Nobar; M Hashemzadeh Chaleshtory; E Farrokhi; M Darabi Amin
Journal:  Iran J Public Health       Date:  2012-01-31       Impact factor: 1.429

View more
  3 in total

1.  Association between the Hepatic Lipase Promoter Region Polymorphism (-514 C/T) and the Presence and Severity of Premature Coronary Artery Disease.

Authors:  Hamidreza Goodarzynejad; Mohammadali Boroumand; Mehrdad Behmanesh; Shayan Ziaee; Arash Jalali; Leyla Pourgholi
Journal:  J Tehran Heart Cent       Date:  2017-07

2.  Hepatic lipase (LIPC) sequencing in individuals with extremely high and low high-density lipoprotein cholesterol levels.

Authors:  Dilek Pirim; Clareann H Bunker; John E Hokanson; Richard F Hamman; F Yesim Demirci; M Ilyas Kamboh
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

Review 3.  Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism.

Authors:  Marcos Palacio Rojas; Carem Prieto; Valmore Bermúdez; Carlos Garicano; Trina Núñez Nava; María Sofía Martínez; Juan Salazar; Edward Rojas; Arturo Pérez; Paulo Marca Vicuña; Natalia González Martínez; Santiago Maldonado Parra; Kyle Hoedebecke; Rosanna D'Addosio; Clímaco Cano; Joselyn Rojas
Journal:  F1000Res       Date:  2017-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.